NOLC1 suppresses immunochemotherapy by inhibiting p53-mediated ferroptosis in gastric cancer
eLife · 27.08.2025 · 13
DOI: 10.7554/elife.103904 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, online erschienen am 27.08.2025. Verfasst von Shengsheng Zhao und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, The First Affiliated Hospital of Wenzhou Medical University Wenzhou, Wenzhou, China. Hauptthemen laut MEDLINE: Ferroptosis, Stomach Neoplasms, Tumor Suppressor Protein p53, Immunotherapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Medical Science and Technology Project of Zhejiang Province.
Abstract (Originalsprache)
Human gastric cancer (GC) is one of the most malignant cancers, and cisplatin (Cis)-based chemotherapy remains the main clinical treatment for GC. However, Cis resistance often occurs, largely limiting its therapeutic efficacy in tumors. Therefore, a better understanding of the drug resistance mechanism could reveal new approaches for improving GC treatment efficacy. Here, we define the integrative role of nucleolar and coiled-body phosphoprotein 1 (NOLC1), a molecular chaperone that is significantly upregulated in GC tissues and Cis-resistant GC cells. Knocking down NOLC1 increased GC sensitivity to Cis by regulating ferroptosis. Mechanistically, NOLC1 binds to the p53 DNA-binding domain (DBD), decreasing p53 nuclear accumulation stimulated by Cis and suppressing p53 transcriptional functions. Then, the p53-mediated ferroptosis is suppressed. Furthermore, the silence of NOLC1 promoted ferroptosis-induced immunogenic cell death (ICD) and reprogrammed the immunosuppressive tumor microenvironment, thereby increasing sensitivity to anti-programmed cell death-1 (PD-1) therapy plus Cis. The combination of anti-PD-1 plus Cis effectively inhibited GC growth without significant side effects. In summary, our findings reveal that targeting NOLC1 may be a novel therapeutic strategy for GC and may increase the efficacy of chemotherapy combined with immune checkpoint inhibitor (ICI) therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastrointestinal Surgery, The First Affiliated Hospital of Wenzhou Medical University Wenzhou, Wenzhou, China.
- Department of Gastrointestinal Surgery, Zhejiang International Scientific and Technological Cooperation Base of Translational Cancer Research, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Med…
- Department of Colorectal and Anal Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
ORCID-Profile: Shengsheng Zhao, Xufeng Lu, Weijian Sun
Förderung
- National Natural Science Foundation of China
- Medical Science and Technology Project of Zhejiang Province
Zitieren
APA
Zhao, S., Lin, J., Zhu, B., Jin, Y., Dong, Q., Ruan, X., Jin, D., Yi, Y., Bai, B., Li, H., Liang, D., Lu, J., Meng, L., Wang, X., Cui, Y., Gu, Y., Shen, X., Lu, X., Rao, S., & Sun, W. (2025). NOLC1 suppresses immunochemotherapy by inhibiting p53-mediated ferroptosis in gastric cancer. eLife, 13. https://doi.org/10.7554/elife.103904
Vancouver
Zhao S, Lin J, Zhu B, Jin Y, Dong Q, Ruan X, et al. NOLC1 suppresses immunochemotherapy by inhibiting p53-mediated ferroptosis in gastric cancer. eLife. 2025;13. doi:10.7554/elife.103904
BibTeX
@article{Zhao2025,
author = {Zhao, Shengsheng and Lin, Ji and Zhu, Bingzi and Jin, Yin and Dong, Qiantong and Ruan, Xiaojiao and Jin, Dan and Yi, Yongdong and Bai, Binglong and Li, Hongzheng and Liang, Danna and Lu, Jianhua and Meng, Letian and Wang, Xiang and Cui, Yuekai and Gu, Yuyang and Shen, Xian and Lu, Xufeng and Rao, Shangrui and Sun, Weijian},
title = {NOLC1 suppresses immunochemotherapy by inhibiting p53-mediated ferroptosis in gastric cancer},
journal = {eLife},
year = {2025},
volume = {13},
doi = {10.7554/elife.103904}
}
EUVIMED